Literature DB >> 3612173

Neuronal size and density in the nucleus basalis of Meynert in Alzheimer's disease.

J O Rinne, L Paljärvi, U K Rinne.   

Abstract

Neuronal size and density were measured in the nucleus basalis of Meynert in 7 elderly patients with Alzheimer's disease (AD) and 7 controls. The number of neurons in AD patients was reduced to 36% of the control value. The population of large neurons (perikaryonal diameter greater than 30 micron) had disappeared almost completely. In addition to cell death, shrinkage may play a role, since there were relatively more neurons in the small size classes in the AD patients than in the controls. The nuclear diameter was reduced to 79% of the control values, and the perikaryonal diameter to 75%, and thus the cytoplasm/nucleus ratio was close to equal in the two groups. Correlations of the morphometric measurements with choline acetyltransferase activities and muscarinic receptor binding are also presented.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612173     DOI: 10.1016/0022-510x(87)90260-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

1.  Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons.

Authors:  Miguel Angel Riudavets; Diego Iacono; Susan M Resnick; Richard O'Brien; Alan B Zonderman; Lee J Martin; Gay Rudow; Olga Pletnikova; Juan C Troncoso
Journal:  Neurobiol Aging       Date:  2007-06-28       Impact factor: 4.673

Review 2.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

3.  Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent.

Authors:  A Salehi; E J Dubelaar; M Mulder; D F Swaab
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

4.  Decreased oligodendrocyte nuclear diameter in Alzheimer's disease and Lewy body dementia.

Authors:  Eva Gagyi; Bernadett Kormos; Karla J Castellanos; Klara Valyi-Nagy; Dennis Korneff; Patrizia LoPresti; Randy Woltjer; Tibor Valyi-Nagy
Journal:  Brain Pathol       Date:  2012-04-12       Impact factor: 6.508

5.  MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia.

Authors:  Haruo Hanyu; Tetsuichi Asano; Hirofumi Sakurai; Yuriko Tanaka; Masaru Takasaki; Kimihiko Abe
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

Review 6.  Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.

Authors:  Donald E Moss; Ruth G Perez
Journal:  Curr Alzheimer Res       Date:  2021       Impact factor: 3.498

7.  HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease.

Authors:  L Mahady; M Nadeem; M Malek-Ahmadi; K Chen; S E Perez; E J Mufson
Journal:  Neuropathol Appl Neurobiol       Date:  2018-10-28       Impact factor: 8.090

8.  Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer disease.

Authors:  S Lehéricy; E C Hirsch; P Cervera; L B Hersh; J J Hauw; M Ruberg; Y Agid
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Signaling pathways mediating a selective induction of nitric oxide synthase II by tumor necrosis factor alpha in nerve growth factor-responsive cells.

Authors:  Michael S Thomas; Wenru Zhang; Paivi M Jordan; H Uri Saragovi; Giulio Taglialatela
Journal:  J Neuroinflammation       Date:  2005-09-06       Impact factor: 8.322

Review 10.  Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.

Authors:  Changiz Geula; Sara R Dunlop; Ivan Ayala; Allegra S Kawles; Margaret E Flanagan; Tamar Gefen; Marek-Marsel Mesulam
Journal:  J Neurochem       Date:  2021-08-06       Impact factor: 5.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.